The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof.

Provided are a plant-derived soft capsule shell having high shell sheet strength, good adhesive property, and good shell performance, and a soft capsule.

A soft capsule shell comprising: (A) iota carrageenan; and (B) waxy corn starch having undergone a heat-moisture treatment in the presence of a salt, the soft capsule shell having a content mass ratio [(A)/(B)] of the component (A) to the component (B) of 0.4 to 3, the soft capsule shell having a content mass ratio [carrageenan/starch] of carrageenan including the component (A) to starch including the component (B) of 0.29 to 1.

A method of making and using a medical delivery device includes forming a first compartment to contain at least a portion of an activator, where forming the first compartment includes forming a first wall with a first ferrous material such that the first wall disintegrates in response to first electromagnetic radiation received by the first ferrous material. Upon contact, the activator activates one or more molecular nanomachines. The method also includes forming a second compartment adjacent to the first wall of the first compartment to contain the one or more molecular nanomachines. The second compartment includes a second wall that includes a second ferrous material. The second wall is configured to disintegrate and release one or more activated molecular nanomachines into a patient in response to second electromagnetic radiation received by the second ferrous material.

An oral enteric delivery system includes an outer shell assembled from multiple solid shell segments joined together by a binder. The binder does not dissolve upon exposure to the gastric environment, but it dissolves in the upper small intestine, causing the shell to disintegrate and causing the payload contained within the shell to be released in the digestive tube downstream of the stomach.

The invention relates to a continuous method for producing inorganic or organic nanoparticles having multiple nuclei functionalised with proteins, using a T-type reactor that operates at high pressure, the primary particles that form the nuclei of the nanoparticles being smaller than 10 nm and said primary particles being immersed in a proteinaceous matrix that forms the nanoparticle in sizes of between 30 nm and 500 nm. The invention also relates to the nanoparticles produced by means of said method.

Disclosed is a microcapsule containing: (i) a microcapsule core having an active material, and (ii) a microcapsule wall formed of a first polymer and second polymer. The first polymer is a sol-gel polymer. The second polymer is gum arabic, purity gum ultra, gelatin, chitosan, xanthan gum, plant gum, carboxymethyl cellulose, sodium carboxymethyl guar gum, or a combination thereof. The weight ratio between the first and second polymer is 1:10 to 10:1. Also disclosed are processes for preparing the microcapsule and uses of the microcapsules in consumer products.

Provided herein is a controlled release and/or sustained release depot drug delivery system, comprising, a biodegradable polymer coating and an API coated with the biodegradable polymer coating, wherein a quantity of API coated with biodegradable polymer is effective to be released. from the biodegradable polymer coating over a prolonged period of time.

The present disclosure relates to compositions of an aqueous colloidal dispersion of hydroxypropyl methyl cellulose acetate succinate (HPMCAS), and methods for making such colloidal dispersions.

The present invention relates to a drug composition and method for treating breast cancer, and more specifically, to use carboxymethyl-hexanoyl chitosan (CHC) to co-encapsulate a heat shock protein 90 (HSP90) inhibitor and a hydrophobic drug. The two drugs can be co-encapsulated with high encapsulation efficiency and co-delivered to breast cancerous cells, and achieve a synergistic efficacy to kill the cancerous cells.

In one aspect, the invention relates to a crystalline form of the structure:

##STR00001##

or a pharmaceutically acceptable salt thereof, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this crystalline form; methods of using this crystalline form and its soluble form (I); and processes for preparing soluble (I) and crystalline (I′) forms.